Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...

Non-smoking women in India face an alarming rise in lung cancer, driven by toxic air and genetic vulnerabilities.

NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reactive molecules suppresses lung tumor growth.

Researchers at NYU said that an experimental drug that blocks a key protein can trigger a form of self-destruction in lung ...

NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reactive molecules suppresses lung tumor growth.

Iovance Biotherapeutics' stock experienced significant upward momentum following the release of encouraging interim results ...

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

The American Society for Radiation Oncology (ASTRO) recently announced the three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer (SCLC) Therapy Challenge, which ...

Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...

October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from ...

The global burden of lung adenocarcinoma (LUAD) has been on the rise, making it among the leading contributor to cancer-related deaths. Long non-coding RNA (lncRNA) are implicated in the initiation ...

Background: Lung adenocarcinoma (LUAD) is one of the common malignant tumors worldwide, and the 5-year survival rate remains unsatisfactory. To investigate the association between ...